{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:51:54Z","timestamp":1792007514640,"version":"4.4.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to systematically analyze the trends in gastric cancer burden in China and globally from 1990 to 2021 using data from the Global Burden of Disease (GBD) database, and to forecast future trends from 2022 to 2036. The findings provide a scientific basis for developing targeted gastric cancer prevention and control policies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Age-standardized incidence rates (ASIR) and age-standardized mortality rates (ASMR) for gastric cancer from 1990 to 2021 were extracted from the GBD database. These data were complemented by GLOBOCAN 2022 statistics to analyze the spatiotemporal characteristics of gastric cancer burden across time, sex, and regions. An autoregressive integrated moving average (ARIMA) model was employed to predict trends from 2022 to 2036.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 1990 to 2021, both ASIR and ASMR for gastric cancer demonstrated significant declines in China and globally. In China, the ASIR decreased from 70.458 per 100,000 in 1990 to 40.125 per 100,000 in 2021 and is projected to further decrease to 25.432 per 100,000 by 2036. Similarly, the ASMR declined from 60.781 per 100,000 in 1990 to 30.214 per 100,000 in 2021 and is forecasted to reach 18.673 per 100,000 by 2036. Globally, the ASIR fell from 35.284 per 100,000 in 1990 to 20.157 per 100,000 in 2021, with a predicted decrease to 12.493 per 100,000 by 2036. Meanwhile, the global ASMR dropped from 30.651 per 100,000 in 1990 to 15.372 per 100,000 in 2021 and is expected to reach 10.284 per 100,000 by 2036. The study also identified significant gender disparities, with males experiencing a substantially higher burden of gastric cancer than females in both China and globally. Furthermore, the age of peak incidence gradually shifted to older age groups, and high-income regions exhibited greater declines in gastric cancer burden compared to low-income regions, highlighting notable regional disparities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Over the past three decades, significant progress has been made in reducing the burden of gastric cancer in China and globally, with declining incidence and mortality rates. These trends are expected to continue in the coming years. However, low-and middle-income countries have seen more limited reductions, with some regions even experiencing increasing burdens. The findings underscore the need for enhanced public health policies focused on preventing <jats:italic>Helicobacter pylori<\/jats:italic> infections, promoting healthy dietary and lifestyle changes, and expanding the coverage of early screening programs. This study provides critical evidence to support the optimization of global and regional gastric cancer prevention and control strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1533544","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:15:32Z","timestamp":1748358932000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The burden and trends of gastric cancer from 1990 to 2021 in China and globally: a cross-sectional study"],"prefix":"10.3389","volume":"12","author":[{"given":"Yulai","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s00203-022-03314-w","article-title":"The impacts of probiotics in eradication therapy of Helicobacter pylori","volume":"204","author":"Bai","year":"2022","journal-title":"Arch Microbiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.21147\/j.issn.1000-9604.2020.06.03","article-title":"Gastric cancer: epidemiology, risk factors and prevention strategies","volume":"32","author":"Yang","year":"2020","journal-title":"Chin J Cancer Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"103841","DOI":"10.1016\/j.critrevonc.2022.103841","article-title":"Characteristics of gastric cancer around the world","volume":"181","author":"L\u00f3pez","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/MOG.0000000000000867","article-title":"Endoscopic methods for the detection and treatment of gastric cancer","volume":"38","author":"Niknam","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.gie.2024.02.036","article-title":"Serology-assisted endoscopic screening for gastric cancer","volume":"100","author":"Menon","year":"2024","journal-title":"Gastrointest Endosc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1016\/S0140-6736(24)00769-4","article-title":"Findings from the global burden of disease study 2021","volume":"403","author":"Murray","year":"2024","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1186\/s12889-022-14642-3","article-title":"Comparison of ARIMA model, DNN model and LSTM model in predicting disease burden of occupational pneumoconiosis in Tianjin, China","volume":"22","author":"Lou","year":"2022","journal-title":"BMC Public Health"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2478\/jos-2020-0003","article-title":"The joinpoint-jump and joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics","volume":"36","author":"Chen","year":"2020","journal-title":"J Off Stat"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"994619","DOI":"10.3389\/fpubh.2022.994619","article-title":"Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1008598","DOI":"10.3389\/fpubh.2022.1008598","article-title":"Trend dynamics of gout prevalence among the Chinese population, 1990-2019: a joinpoint and age-period-cohort analysis","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Public Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"7945","DOI":"10.3390\/ijms24097945","article-title":"Effects of probiotic Saccharomyces boulardii supernatant on viability, nano-mechanical properties of cytoplasmic membrane and pro-inflammatory gene expression in human gastric cancer AGS cells","volume":"24","author":"Pakbin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1038\/s41591-024-03153-w","article-title":"Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial","volume":"30","author":"Pan","year":"2024","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1053\/j.gastro.2023.12.022","article-title":"Global prevalence of Helicobacter pylori infection and incidence of gastric cancer between 1980 and 2022","volume":"166","author":"Chen","year":"2024","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1395403","DOI":"10.3389\/fmicb.2024.1395403","article-title":"The immunopathogenesis of Helicobacter pylori-induced gastric cancer: a narrative review","volume":"15","author":"Shirani","year":"2024","journal-title":"Front Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100890","DOI":"10.1016\/j.lana.2024.100890","article-title":"Helicobacter pylori infection in the United States beyond NHANES: a scoping review of seroprevalence estimates by racial and ethnic groups","volume":"41","author":"McMahon","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s15010-024-02244-7","article-title":"Estimates of global and regional prevalence of Helicobacter pylori infection among individuals with obesity: a systematic review and meta-analysis","volume":"52","author":"Sadeghi","year":"2024","journal-title":"Infection"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s10120-024-01502-9","article-title":"Adding salt to food at table as an indicator of gastric cancer risk among adults: a prospective study","author":"Kronsteiner-Gicevic","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40273-024-01413-8","article-title":"Systematic review of economic evaluations of systemic treatments for advanced and metastatic gastric cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3748\/wjg.v30.i8.779","article-title":"Immunotherapy of gastric cancer: present status and future perspectives","volume":"30","author":"Triantafillidis","year":"2024","journal-title":"World J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1007\/s12602-022-10030-w","article-title":"Anticancer properties of Saccharomyces boulardii metabolite against colon cancer cells","volume":"16","author":"Pakbin","year":"2024","journal-title":"Probiotics Antimicrob Proteins"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1533544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:15:33Z","timestamp":1748358933000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1533544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":21,"alternative-id":["10.3389\/fmed.2025.1533544"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1533544","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1533544"}}